Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ruby De La Torre

Nurse Practitioner, Family Aurora, IL Nurse Practitioner

NPI 1851764146 CMS profile 10490952

400 N Highland Ave, Vna Health Care, Aurora, IL 60506

Open in the dashboard

General payments

$16,576

887 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ruby De La Torre of Aurora, IL is reported in the CMS Open Payments database as having received $16,576 across 887 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,319 236
2024 General $5,122 261
2023 General $4,200 224
2022 General $2,327 137
2021 General $608 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ruby De La Torre
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Ruby De La Torre were reported at $4,319. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Ruby De La Torre Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $608 $124 $35–$379 $132
2022 $2,327 $141 $44–$430 $149
2023 $4,200 $154 $49–$476 $160
2024 $5,122 $165 $51–$504 $164
2025 $4,319 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $2,026 106 payments
  2. AbbVie, Inc. $2,008 113 payments
  3. Sun Pharmaceutical Industries Inc. $1,252 55 payments
  4. Regeneron Healthcare Solutions, Inc. $1,225 47 payments
  5. Lilly USA, LLC $1,179 63 payments
  6. Pfizer Inc. $1,155 94 payments
  7. Dermavant Sciences, Inc. $1,103 67 payments
  8. Incyte Corporation $1,073 43 payments
  9. Novartis Pharmaceuticals Corporation $954 62 payments
  10. E.R. Squibb & Sons, L.L.C. $872 39 payments
  11. Other $3,728 198 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $15,471 871 payments
  2. Education $1,043 15 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $62 1 payment
Products named General payments · program years 2021–2025
  1. TREMFYA $2,109 106 payments
  2. VTAMA $1,170 75 payments
  3. CIBINQO $1,126 91 payments
  4. OPZELURA $1,073 43 payments
  5. RINVOQ $957 59 payments
  6. SOTYKTU $863 38 payments
  7. SKYRIZI $798 39 payments
  8. EUCRISA $750 63 payments
  9. DUPIXENT $624 20 payments
  10. LITFULO $584 50 payments
  11. Other $8,927 528 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

697

Median for Nurse Practitioner: 389

Drug cost

$442,475

Median for Nurse Practitioner: $21,885

Branded share of claims

20.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 32 $278,464
Dupixent Pen Dupilumab Brand 18 $80,702
Otezla Apremilast Brand 14 $67,517
Betamethasone Dipropionate Generic 132 $4,924
Tacrolimus Generic 17 $2,622
Triamcinolone Acetonide Generic 122 $1,604
Ciclopirox Ciclopirox Olamine Brand 47 $1,032
Clobetasol Propionate Generic 32 $1,024
Metronidazole Generic 30 $904
Ketoconazole Generic 56 $878

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$75,496

Of which drugs: $1,653

Medicare patients

521

Average age 74

Services billed

3,263

329 women, 192 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 48%
Ischemic heart disease 25%
Diabetes 23%
Chronic kidney disease 21%
Osteoporosis 18%
COPD 17%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 79 $43

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VTAMA
$880 — —
TREMFYA
$655 — —
SOTYKTU
$360 — —
SKYRIZI
$318 — —
OPZELURA
$315 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

887 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record